45 results on '"Capela, João Paulo"'
Search Results
2. Protective effects of amphetamine and methylphenidate against dopaminergic neurotoxicants in SH-SY5Y cells
- Author
-
Carneiro, Patrícia, Ferreira, Mariana, Marisa Costa, Vera, Carvalho, Félix, and Capela, João Paulo
- Published
- 2024
- Full Text
- View/download PDF
3. Ecstasy metabolites and monoamine neurotransmitters upshift the Na+/K+ ATPase activity in mouse brain synaptosomes
- Author
-
Barbosa, Daniel José, Capela, João Paulo, Ferreira, Luísa Maria, Branco, Paula Sério, Fernandes, Eduarda, de Lourdes Bastos, Maria, and Carvalho, Félix
- Published
- 2022
- Full Text
- View/download PDF
4. Amphetamine and methylphenidate potential on the recovery from stroke and traumatic brain injury: a review
- Author
-
Ferreira, Mariana, primary, Carneiro, Patrícia, additional, Costa, Vera Marisa, additional, Carvalho, Félix, additional, Meisel, Andreas, additional, and Capela, João Paulo, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Chemobrain: mitoxantrone-induced oxidative stress, apoptotic and autophagic neuronal death in adult CD-1 mice
- Author
-
Dias-Carvalho, Ana, Ferreira, Mariana, Reis-Mendes, Ana, Ferreira, Rita, Bastos, Maria Lourdes, Fernandes, Eduarda, Sá, Susana Isabel, Capela, João Paulo, Carvalho, Félix, and Costa, Vera Marisa
- Published
- 2022
- Full Text
- View/download PDF
6. Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events
- Author
-
Dias-Carvalho, Ana, Ferreira, Mariana, Ferreira, Rita, Bastos, Maria de Lourdes, Sá, Susana Isabel, Capela, João Paulo, Carvalho, Félix, and Costa, Vera Marisa
- Published
- 2022
- Full Text
- View/download PDF
7. A review on the mitochondrial toxicity of “ecstasy” (3,4-methylenedioxymethamphetamine, MDMA)
- Author
-
Capela, João Paulo and Carvalho, Félix Dias
- Published
- 2022
- Full Text
- View/download PDF
8. An updated review on synthetic cathinones
- Author
-
Soares, Jorge, Costa, Vera Marisa, Bastos, Maria de Lourdes, Carvalho, Félix, and Capela, João Paulo
- Published
- 2021
- Full Text
- View/download PDF
9. Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations
- Author
-
Costa, Vera Marisa, Capela, João Paulo, Sousa, Joana R., Eleutério, Rute P., Rodrigues, Patrícia R. S., Dores-Sousa, José Luís, Carvalho, Rui A., Lourdes Bastos, Maria, Duarte, José Alberto, Remião, Fernando, Almeida, M. Gabriela, Varner, Kurt J., and Carvalho, Félix
- Published
- 2020
- Full Text
- View/download PDF
10. Adverse outcome pathways induced by 3,4-dimethylmethcathinone and 4-methylmethcathinone in differentiated human SH-SY5Y neuronal cells
- Author
-
Soares, Jorge, Costa, Vera Marisa, Gaspar, Helena, Santos, Susana, Bastos, Maria de Lourdes, Carvalho, Félix, and Capela, João Paulo
- Published
- 2020
- Full Text
- View/download PDF
11. Study of the potential toxicity of adrenaline to neurons, using the SH-SY5Y human cellular model
- Author
-
Costa, Vera Marisa, primary, Capela, João Paulo, additional, Bastos, Maria Lourdes, additional, Remião, Fernando, additional, Varner, Kurt James, additional, Duarte, José Alberto, additional, and Carvalho, Félix, additional
- Published
- 2023
- Full Text
- View/download PDF
12. Involvement of Mitochondrial Dysfunction on the Toxic Effects Caused by Drugs of Abuse and Addiction
- Author
-
Barbosa, Daniel José, primary, Capela, João Paulo, additional, de Lourdes Bastos, Maria, additional, and Carvalho, Félix, additional
- Published
- 2018
- Full Text
- View/download PDF
13. Doxorubicin-induced neurotoxicity differently affects the hippocampal formation subregions in adult mice
- Author
-
Dias-Carvalho, Ana, primary, Ferreira, Mariana, additional, Reis-Mendes, Ana, additional, Ferreira, Rita, additional, Bastos, Maria Lourdes, additional, Fernandes, Eduarda, additional, Sá, Susana Isabel, additional, Capela, João Paulo, additional, Carvalho, Félix, additional, and Costa, Vera Marisa, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Mitochondria: key players in the neurotoxic effects of amphetamines
- Author
-
Barbosa, Daniel José, Capela, João Paulo, Feio-Azevedo, Rita, Teixeira-Gomes, Armanda, Bastos, Maria de Lourdes, and Carvalho, Félix
- Published
- 2015
- Full Text
- View/download PDF
15. Mitoxantrone-induced neurotoxicity in CD-1 mice
- Author
-
Dias-Carvalho, Ana, primary, Ferreira, Mariana, additional, Reis Mendes, Ana, additional, Ferreira, Rita, additional, Fernandes, Eduarda, additional, Isabel Sá, Susana, additional, Capela, João Paulo, additional, Carvalho, Félix, additional, and Costa, Vera Marisa, additional
- Published
- 2022
- Full Text
- View/download PDF
16. Potential health risks surrounding ingredients of pre-workout and post-workout dietary supplements: a thorough label analysis
- Author
-
MARQUES, João Nuno Alves do Vale, primary and CAPELA, João Paulo, additional
- Published
- 2022
- Full Text
- View/download PDF
17. Mitochondrial Trails in the Neurotoxic Mechanisms of MDMA
- Author
-
Barbosa, Daniel José, primary, Capela, João Paulo, additional, de Lourdes Bastos, Maria, additional, and Carvalho, Félix, additional
- Published
- 2016
- Full Text
- View/download PDF
18. List of Contributors
- Author
-
Abdalla, Renata Rigacci, primary, Abekawa, Tomohiro, additional, Adamczyk, Przemysław, additional, Adams, Wendy, additional, Addy, Peter H., additional, Ago, Yukio, additional, Álvaro-Bartolomé, María, additional, Andellini, Martina, additional, Andrzejewski, Matthew E., additional, Angarita, Gustavo A., additional, Angoa-Pérez, Mariana, additional, Anneken, John H., additional, Antunes, Luís, additional, Ardakani, Yalda Hosseinzadeh, additional, Aydin, Mustafa, additional, Badri, Nima, additional, Bajpai, Ram C., additional, Barbosa, Daniel José, additional, Barrós-Loscertales, Alfonso, additional, Basu, Debasish, additional, Becker, Benjamin, additional, Beckley, Jacob T., additional, Bermejo, Pablo García, additional, Berro, Laís F., additional, Blaker, Amanda L., additional, Bodoki, Ede, additional, Borowiak, Krzysztof, additional, Bowen, Scott E., additional, Broderick, Patricia A., additional, Brogaard, Berit, additional, Brolese, Giovana, additional, Brunt, T.M., additional, Buchborn, T., additional, Butelman, Eduardo R., additional, Caetano, Raul, additional, Campos, Sónia, additional, Canavan, Sofija V., additional, Capela, João Paulo, additional, Carta, Manolo, additional, Carvalho, Félix, additional, Carvelli, Lucia, additional, Catlow, Briony J., additional, Chang, Young-Tae, additional, Chaturvedi, Himanshu K., additional, Chilachava, Lela, additional, Choodum, Aree, additional, Clough, Shannon J., additional, Coelho-Santos, Vanessa, additional, Coimbra, Ana Maria, additional, Collins, Stuart A., additional, Cormand, Bru, additional, Dahan, Albert, additional, Dakwar, Elias, additional, Dávalos E., Antonio, additional, de Jong, Cor, additional, de Lourdes Bastos, Maria, additional, Del Bigio, Marc R., additional, Dembińska, Teresa, additional, Deveci, Ugur, additional, Dieterich, D.C., additional, Dijkstra, Boukje, additional, Dluzen, Dean E., additional, Dubocovich, Margarita L., additional, Esperón, Carlos García, additional, Fang, Chun-Kai, additional, Farnia, Vahid, additional, Félix, Luís, additional, Fernàndez-Castillo, Noelia, additional, Flack, Daniel, additional, Frauger, Elisabeth, additional, Frohlich, Joel, additional, Fukushiro, Daniela F., additional, García, Daniel A., additional, Julia García-Fuster, M., additional, García-Sevilla, Jesús A., additional, Garland, Eric L., additional, Gatzia, Dimitria Electra, additional, Gelazonia, Lia, additional, Ghosh, Abhishek, additional, Gigengack, Roy, additional, Golshani, Senobar, additional, Gonçalves, Joana, additional, González-Maeso, Javier, additional, Gorman, Ingmar, additional, Grandy, David K., additional, Grecksch, G., additional, Greer, Alissa M., additional, Gudelsky, Gary A., additional, Guillot, Casey, additional, Gulley, Joshua M., additional, Hagino, Yoko, additional, Hallock, Robert M., additional, Hankosky, Emily R., additional, Hanks, James B., additional, Hart, Carl, additional, Hasselmann, H.W.W., additional, Hida, Hirotake, additional, Hodges, Sarah E., additional, Holder, Nicole, additional, Hollais, André W., additional, Höllt, V., additional, Horacek, Jiri, additional, Howard, Matthew O., additional, Howells, Fleur Margaret, additional, Hsin-Hsien Yeh, Skye, additional, Huang, Mei, additional, Hutchinson, Anthony J., additional, Hwang, Jeng-Jong, additional, Ikeda, Kazutaka, additional, Iudicello, Jennifer E., additional, Jalloh, Ahmad, additional, Jamali, Bardia, additional, Japaridze, Nadezhda, additional, Jodo, Eiichi, additional, Joordens, Chantele, additional, Kalayasiri, Rasmon, additional, Kamal, Rama, additional, Kamegaya, Etsuko, additional, Katayama, Tadahiro, additional, Keasling, Adam W., additional, Kikura-Hanajiri, Ruri, additional, Kirkpatrick, Matthew, additional, Kiss, Béla, additional, Kočárová, Rita, additional, Kokane, Saurabh S., additional, Kreek, Mary Jeanne, additional, Kufahl, Peter R., additional, Kuhn, Donald M., additional, Kumazawa, Takeshi, additional, Kusljic, Snezana, additional, Łabuz, Krzysztof, additional, Lapeyre-Mestre, Maryse, additional, Laranjeira, Ronaldo Ramos, additional, Lawrence, Andrew J., additional, Lee, Byung Dae, additional, Leitão, Ricardo Alexandre, additional, Leung, L. Stan, additional, Li, Chiang-Shan R., additional, Li, Meng, additional, Lin, Qing, additional, Loghin, Felicia, additional, López-Cancio M., Elena, additional, Lyke, Jennifer, additional, Lyvers, Michael, additional, Macdonald, Scott, additional, Madruga, Clarice Sandi, additional, Maes, Michael, additional, Maher, Timothy J., additional, Ma, Jingyi, additional, Mandyam, Chitra D., additional, Mardones, Claudia, additional, Martin, Gina, additional, Massaro, Luciana, additional, Matsuda, Toshio, additional, McMaster, M.T.B., additional, Melloni, Richard H., additional, Meltzer, Herbert Y., additional, Micallef, Joëlle, additional, Mironidou-Tzouveleki, Maria, additional, Mishina, Masayoshi, additional, Mitsuhiro, Sandro, additional, Montag, Christian, additional, Moore, Elisabeth, additional, Morgan, Erin E., additional, Morgan, Peter T., additional, Morimoto, Satoshi, additional, Morrison, Thomas R., additional, Moszczynska, Anna, additional, Mouri, Akihiro, additional, Napolitano, Antonio, additional, Neugebauer, Nichole M., additional, NicDaeid, Niamh, additional, Nichols, Charles D., additional, Nizama-Valladolid, Martin, additional, Noda, Yukihiro, additional, Northrop, Nicole A., additional, Olive, M. Foster, additional, Ostrow, Rory D., additional, Oudejans, Linda C.J., additional, Palenicek, Tomas, additional, Pandey, Arvind, additional, Papp, Mariusz, additional, Passos, Ioannis D., additional, Paudel, Madan Kumar, additional, Perillo, Maria A., additional, Perry, Christina J., additional, Petronijević, Nataša, additional, Phattanarudee, Siripan, additional, Pinsky, Ilana, additional, Pochkhidze, Nino, additional, Pop, Anca, additional, Possa, Marianne, additional, Potocka-Banaś, Barbara, additional, Quednow, Boris B., additional, Radonjić, Nevena V., additional, Rajagopal, Lakshmi, additional, Ribasés, Marta, additional, Ricci, Lesley A., additional, Rosales, Carola Vergara, additional, Rouini, Mohammad-Reza, additional, Sanchez-Ramos, Juan, additional, Santos-Baldaia, Renan, additional, Sarkar, Siddharth, additional, Sasaki-Tabata, Kaori, additional, Sato, Naomi, additional, Sato, Tomonori, additional, Sawada, Wakako, additional, Schuch, Silvia Bassani, additional, Sekita, Setsuko, additional, Serrano, Eduardo Alvear, additional, Sheikholeslami, Behjat, additional, Shirota, Osamu, additional, Silva, Ana Paula, additional, Simola, Nicola, additional, Simon, Derek P., additional, Sora, Ichiro, additional, Sordi, Anne Orgler, additional, Spring, Mitchell G., additional, Stebelska, Katarzyna, additional, Sugimura, Haruhiko, additional, Suzuki, Yoshiaki, additional, Takuma, Kazuhiro, additional, Tanaka, Hiroyuki, additional, Torkamanian, Meshkat, additional, Towiwat, Pasarapa, additional, Turina, Anahí V., additional, Tyls, Filip, additional, van Amsterdam, J.G.C., additional, van den Brink, W., additional, van den Buuse, Maarten, additional, Van Horn, John Darrell, additional, van Noorden, Martijn, additional, van Velzen, Monique, additional, Venâncio, Carlos, additional, von Baer, Dietrich, additional, von Diemen, Lisia, additional, Walter, Martin, additional, Wang, Fang, additional, Weber, Erica, additional, Winkler, Petr, additional, Woods, Steven Paul, additional, Woodward, John J., additional, Wu, Chun-Fu, additional, Wuo-Silva, Raphael, additional, Xu, Wang, additional, Yamamoto, Bryan K., additional, Yamamoto, Hideko, additional, Yamamoto, Toshifumi, additional, Yang, Jing-Yu, additional, Zhai, Duanting, additional, Zhvania, Mzia, additional, and Zjawiony, Jordan K., additional
- Published
- 2016
- Full Text
- View/download PDF
19. Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events
- Author
-
Dias-Carvalho, Ana, primary, Ferreira, Mariana, additional, Ferreira, Rita, additional, Bastos, Maria de Lourdes, additional, Sá, Susana Isabel, additional, Capela, João Paulo, additional, Carvalho, Félix, additional, and Costa, Vera Marisa, additional
- Published
- 2021
- Full Text
- View/download PDF
20. Ecstasy metabolites and monoamine neurotransmitters upshift the Na+/K+ ATPase activity in mouse brain synaptosomes.
- Author
-
Barbosa, Daniel José, Capela, João Paulo, Ferreira, Luísa Maria, Branco, Paula Sério, Fernandes, Eduarda, de Lourdes Bastos, Maria, and Carvalho, Félix
- Subjects
- *
SYNAPTOSOMES , *METABOLITES , *SEROTONIN , *NEUROTRANSMITTERS , *PROTEIN kinases , *DOPAMINE , *PSYCHIATRIC drugs , *ADENOSINE triphosphatase - Abstract
3,4-Methylenedioximethamphetamine (MDMA; "ecstasy") is a psychotropic drug with well-known neurotoxic effects mediated by hitherto not fully understood mechanisms. The Na+- and K+-activated adenosine 5′-triphosphatase (Na+/K+ ATPase), by maintaining the ion gradient across the cell membrane, regulates neuronal excitability. Thus, a perturbation of its function strongly impacts cell homeostasis, ultimately leading to neuronal dysfunction and death. Nevertheless, whether MDMA affects the Na+/K+ ATPase remains unknown. In this study, we used synaptosomes obtained from whole mouse brain to test the effects of MDMA, three of its major metabolites [α-methyldopamine, N-methyl-α-methyldopamine and 5-(glutathion-S-yl)-α-methyldopamine], serotonin (5-HT), dopamine, 3,4-dihydroxy-l-phenylalanine (l-Dopa) and 3,4-dihydroxyphenylacetic acid (DOPAC) on the Na+/K+ ATPase function. A concentration-dependent increase of Na+/K+ ATPase activity was observed in synaptosomes exposed to the tested compounds (concentrations ranging from 0.0625 to 200 µM). These effects were independent of protein kinases A and C activities. Nevertheless, a rescue of the compounds' effects was observed in synaptosomes pre-incubated with the antioxidant N-acetylcysteine (1 mM), suggesting a role for reactive species-regulated pathways on the Na+/K+ ATPase effects. In agreement with this hypothesis, a similar increase in the pump activity was found in synaptosomes exposed to the chemical generator of superoxide radicals, phenazine methosulfate (1–250 µM). This study demonstrates the ability of MDMA metabolites, monoamine neurotransmitters, l-Dopa and DOPAC to alter the Na+/K+ ATPase function. This could represent a yet unknown mechanism of action of MDMA and its metabolites in the brain. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Chapter 6 - Chemobrain
- Author
-
Costa, Vera Marisa, Dias Carvalho, Ana Rita, Capela, Joao Paulo, and Carvalho, Felix
- Published
- 2021
- Full Text
- View/download PDF
22. Structure-cytotoxicity relationship profile of 13 synthetic cathinones in differentiated human SH-SY5Y neuronal cells
- Author
-
Soares, Jorge, primary, Costa, Vera Marisa, additional, Gaspar, Helena, additional, Santos, Susana, additional, de Lourdes Bastos, Maria, additional, Carvalho, Félix, additional, and Capela, João Paulo, additional
- Published
- 2019
- Full Text
- View/download PDF
23. Effects of Doxorubicin and Mitoxantrone in the brain of differently aged mice: in vivo chemobrain study
- Author
-
Dias-Carvalho, Ana, primary, Reis-Mendes, Ana, additional, Duarte-Araújo, Margarida, additional, Carvalho, Félix, additional, Bastos, Maria Lourdes, additional, Sá, Susana I., additional, Capela, João Paulo, additional, and Costa, Vera Marisa, additional
- Published
- 2019
- Full Text
- View/download PDF
24. Suplementos alimentares para emagrecimento contendo sinefrina: riscos e toxicidade
- Author
-
Alves, Mariana Catarina Ribeiro and Capela, João Paulo
- Subjects
Cafeína ,Sinefrina ,Termogénese ,Synephrine ,Sietary supplement ,Cardiovascular toxicity ,Toxicidade cardiovascular ,Peso corporal ,Thermogenesis ,Suplemento alimentar ,Body weight ,Citrus aurantium - Abstract
Introdução: A sinefrina é o principal composto ativo presente no Citrus aurantium. Encontra-se incorporada em muitos suplementos alimentares que advogam promover a perda de peso, isto apesar do efeito termogénico e a segurança da sinefrina carecerem de estudos que os comprovem. Diversas autoridades de segurança alimentar internacionais emitiram recomendações sobre níveis máximos de consumo diários. Objetivos: Estudar a composição dos suplementos alimentares para emagrecimento contendo sinefrina e/ou Citrus aurantium disponíveis no mercado português e analisar os efeitos adversos associados às doses diárias de sinefrina que apresentam. Metodologia: Para a pesquisa de suplementos alimentares para emagrecimento com sinefrina, foi realizada uma pesquisa em pontos de venda físicos e sítios da internet, entre março e abril de 2018. Resultados: Reuniram-se 37 suplementos com sinefrina e/ou Citrus aurantium na sua composição, apenas sendo possível inferir sobre a quantidade de sinefrina presente em 16 suplementos. Aferiu-se que a dose diária de extrato de Citrus aurantium recomendada pelo produtor e/ou distribuidor corresponde a um valor mediano de 200 mg com valor mínimo de 6 mg e o valor máximo de 840 mg. A quantidade mediana de sinefrina diária recomendada é de 12 mg, com um valor mínimo de 0,6 mg e valor máximo de 60 mg. A cafeína anidra e a sinefrina encontram-se combinadas em 9 suplementos. Vários suplementos excedem os limites diários de sinefrina recomendados por autoridades de segurança alimentar, de destacar que 13 dos 16 suplementos, em que foi possível estimar o valor de sinefrina, excedem os limites preconizados pela autoridade alemã BfR. Conclusões: Os níveis de sinefrina presentes em vários suplementos podem ser danosos para a saúde dos consumidores. O risco cardiovascular da sinefrina é aumentado na presença de cafeína. Os consumidores devem ser alertados para os níveis destes compostos presentes nos suplementos. Introduction: Synephrine is the main active compound present in Citrus aurantium. It is found in many dietary supplements that advocate the promotion of weight loss, despite the limited availability of studies that prove the thermogenic effect and safety of synephrine. Several international food safety authorities issued recommendations on the maximum daily levels. Objectives: Study the composition of dietary supplements containing synephrine and/or Citrus aurantium available in the Portuguese market and analyze the adverse effects associated with their synephrine daily doses. Methodology: To find dietary supplements for weight loss with synephrine, it was carried out a research at local stores and internet websites, between March 2018 and April 2018. Results: 37 supplements containing synephrine and/or Citrus aurantium were found, but it is only possible to infer about the amount of synephrine in 16 supplements. It was assessed that the Citrus aurantium daily dose recommended by the producer and/or distributor corresponds to a median value of 200 mg, with a minimum value of 6 mg and a maximum value of 840 mg. The median amount of daily synephrine recommended is 12 mg, with a maximum value of 60 mg and a minimum value of 0.6 mg. Anhydrous caffeine and synephrine were combined in 9 supplements. Several supplements exceed the daily dose limits of synephrine recommended by food safety authorities, of note that 13 of the 16 supplements, where it was possible to estimate the daily dose of synephrine, exceed the limits recommended by the German BfR authority. Conclusions: Synephrine daily levels present in various supplements can be dangerous to health consumers. The cardiovascular risk of synephrine is increased in combination with caffeine. Consumers should be alerted to the levels of these compounds present in dietary supplements.
- Published
- 2019
25. Suplementos alimentares para emagrecimento contendo sinefrina: riscos e toxicidade
- Author
-
Alves,Mariana Catarina Ribeiro and Capela,João Paulo
- Subjects
Cafeína ,Sinefrina ,Termogénese ,Toxicidade cardiovascular ,Peso corporal ,Suplemento alimentar ,Citrus aurantium - Published
- 2019
26. Monitorização e notificação de efeitos adversos ao sistema de Farmacovigilância Europeu da nova terapêutica para a Hepatite C
- Author
-
Costa, Cláudia, FP-ENAS (Unidade de Investigação UFP em Energia, Ambiente e Saúde), CEBIMED (Centro de Estudos em Biomedicina), Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Portugal., Marques, Joana, Centre for Research in Health Technologies and Information Systems (CINTESIS), Faculdade de Medicina da Universidade do Porto, Portugal, Capela, João Paulo, and UCIBIO/REQUIMTE (Rede de Química e Tecnologia), Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Portugal.
- Subjects
Hepatite C, vírus da Hepatite C, Harvoni®, efeitos adversos, notificação, farmacovigilância - Published
- 2017
27. List of contributors
- Author
-
Adani, Giorgia, Agathokleous, Evgenios, Aloizou, Athina-Maria, Anadon, Arturo, Antoniou, Michael, Ares, Irma, Aschner, Michael, Aslanoglou, Katerina, Avila, Daiana Silva, Berselli, Nausicaa, Biosca-Brull, J., Bogdanos, Dimitrios P., Briggs, Michael B., Calabrese, Edward J., Calina, Daniela, Capela, Joao Paulo, Carmo, Helena, Carvalho, Felix, Chandrasekaran, N., Colomina, M.T., Constantin, Carolina, Corsini, Emanuela, Costa, Chiara, Costa, Vera Marisa, Dardiotis, Efthimios, de Oliveira, Carlos Augusto Fernandes, de Oliveira Pereira, Flavia Suelen, Del Gaudio, Pasquale, Deng, Tianqi, Dias Carvalho, Ana Rita, Djordjevic, Aleksandra Buha, Docea, Anca Oana, Drakoulis, Nikolaos, Farsalinos, Konstantinos, Fenga, Concettina, Filippini, Tommaso, Flouris, Andreas D., Fragkiadaki, Persefoni, Fragou, Domniki, Franco, Larissa Tuanny, Fu, Jingqi, Galbiati, Valentina, Garcia-Gonzalez, Carlos A., Georgaki, Spyridoula, Giusi, Briguglio, Gkikas, Giorgos, Golokhvast, Kirill, Gomes, Telma M., Goumenou, Marina, Guardia-Escote, L., Guo, Jiabin, Hartung, Thomas, Hernandez, Antonio F., Hossain, Ekhtear, Ioannou, Leonidas G., Kandarova, Helena, Karakitsios, Spyros P., Karzi, Vasiliki, Kochiadakis, George E., Kostoff, Ronald N., Kovatsi, Leda, Kuhlman, Christopher L., Kyriakos, Christina, Lagou, Ioanna, Lash, Lawrence H., Liampas, Ioannis, Lipscomb, John C., Liu, Shengnan, Maddalon, Ambra, Malheiro, Rui F., Mantzios, Konstantinos, Margina, Denisa, Martinez, Maria-Aranzazu, Martinez, Marta, Martinez-Larranaga, Maria-Rosa, Mesnage, Robin, Mitsias, Panayiotis D., Morales, M., Muaz, Khurram, Mukherjee, Amitava, Neagu, Monica, Nikitara, Katerina, Nikitovic, Dragana, Nikolouzakis, Taxiarchis Konstantinos, Nitulescu, George Mihai, Nitulescu, Georgiana, Olaru, Octavian Tudorel, Ota, Akinobu, Ozcagli, Eren, Papasavva, Maria, Pateraki, Georgia, Perez-Fernandez, C., Pi, Jingbo, Pikula, Konstantin, Porter, Alan L., Purdel, Carmen, Qu, Weidong, Raman, Thiagarajan, Renieri, Elisavet, Rezaee, Ramin, Sanchez-Santed, F., Sarandi, Evangelia, Sarigiannis, Dimosthenis A., Sarkar, Kasturi, Seenivasan, R., Sil, Parames C., Silva, Joao P., Siokas, Vasileios, Soares, Marcell Valandro, Stemmer, Paul M., Thiagarajan, Vignesh, Tsarouhas, Konstantinos, Tsatsakis, Aristidis M., Tsatsakis, Ioannis, Tsitsimpikou, Christina, Tsoukalas, Dimitris, Tsoutsoubi, Lydia, Ungurianu, Anca, Vakonaki, Elena, Vardavas, Alexander, Vardavas, Constantine, Vassilopoulou, Loukia, Veskoukis, Aristidis S., Vinceti, Marco, Vives Enrich, Marc, Vlata, Zacharenia, Wahiduzzaman, Md, Wallace, Heather M., Wang, Huihui, Xu, Yuanyuan, and Zhang, Qiang
- Published
- 2021
- Full Text
- View/download PDF
28. Chapter 40 - Mitochondrial Trails in the Neurotoxic Mechanisms of MDMA
- Author
-
Barbosa, Daniel José, Capela, João Paulo, de Lourdes Bastos, Maria, and Carvalho, Félix
- Published
- 2016
- Full Text
- View/download PDF
29. Methylphenidate clinically oral doses improved brain and heart glutathione redox status and evoked renal and cardiac tissue injury in rats
- Author
-
Loureiro-Vieira, Sara, primary, Costa, Vera Marisa, additional, Duarte, José Alberto, additional, Duarte-Araújo, Margarida, additional, Gonçalves-Monteiro, Salomé, additional, Maria de Lourdes, Bastos, additional, Carvalho, Félix, additional, and Capela, João Paulo, additional
- Published
- 2018
- Full Text
- View/download PDF
30. Pharmacology and Toxicology of Amphetamine-Type Stimulants.
- Author
-
Capela, João Paulo and Costa, Vera Marisa
- Subjects
- *
AMPHETAMINES , *PHARMACOLOGY , *NEUROTRANSMITTERS , *CHEMICAL structure , *ATTENTION-deficit hyperactivity disorder - Published
- 2023
- Full Text
- View/download PDF
31. Methylphenidate effects in the young brain: friend or foe?
- Author
-
Loureiro‐Vieira, Sara, primary, Costa, Vera Marisa, additional, Lourdes Bastos, Maria, additional, Carvalho, Félix, additional, and Capela, João Paulo, additional
- Published
- 2017
- Full Text
- View/download PDF
32. “Ecstasy” toxicity to adolescent rats following an acute low binge dose
- Author
-
Teixeira-Gomes, Armanda, primary, Costa, Vera Marisa, additional, Feio-Azevedo, Rita, additional, Duarte, José Alberto, additional, Duarte-Araújo, Margarida, additional, Fernandes, Eduarda, additional, Bastos, Maria de Lourdes, additional, Carvalho, Félix, additional, and Capela, João Paulo, additional
- Published
- 2016
- Full Text
- View/download PDF
33. In vitro models for neurotoxicology research
- Author
-
Barbosa, Daniel José, primary, Capela, João Paulo, additional, de Lourdes Bastos, Maria, additional, and Carvalho, Félix, additional
- Published
- 2015
- Full Text
- View/download PDF
34. The neurotoxicity of amphetamines during the adolescent period
- Author
-
Teixeira‐Gomes, Armanda, primary, Costa, Vera Marisa, additional, Feio‐Azevedo, Rita, additional, Bastos, Maria de Lourdes, additional, Carvalho, Félix, additional, and Capela, João Paulo, additional
- Published
- 2014
- Full Text
- View/download PDF
35. Amphetamine and its metabolite 4-hydroxyamphetamine neurotoxicity in differentiated SH-SY5Y neurons
- Author
-
Feio-Azevedo, Rita, primary, Costa, Vera Marisa, additional, Ferreira, Luísa Pinto, additional, Branco, Paula Sério, additional, Pereira, Frederico Costa, additional, de Lourdes Bastos, Maria, additional, Carvalho, Félix, additional, and Capela, João Paulo, additional
- Published
- 2014
- Full Text
- View/download PDF
36. The neurotoxicity of amphetamines during the adolescent period.
- Author
-
Teixeira-Gomes, Armanda, Costa, Vera Marisa, Feio-Azevedo, Rita, Bastos, Maria de Lourdes, Carvalho, Félix, and Capela, João Paulo
- Published
- 2015
- Full Text
- View/download PDF
37. In vitromodels for neurotoxicology research
- Author
-
Barbosa, Daniel José, Capela, João Paulo, de Lourdes Bastos, Maria, and Carvalho, Félix
- Abstract
The nervous system has a highly complex organization, including many cell types with multiple functions, with an intricate anatomy and unique structural and functional characteristics. The study of its (dys)functionality following exposure to xenobiotics, neurotoxicology, constitutes an important issue in neurosciences. Despite the extensive use of in vivomodels to reveal the neurotoxicological phenomena, the existence of difficulties related to the increasing cost and time required for neurotoxicity studies with experimental animals, as well as the animal ethical concerns, have limited their use. Consequently, in vitroalternatives, providing an understanding of the mechanistic basis, at the molecular and cellular level, have earned a notable consideration in the field of neurotoxicological research. In this field, the selection of the most appropriate in vitroneuronal system relies on specific endpoints that are of particular relevance for the neurotoxicological phenomena that will be studied. Furthermore, application of specific endpoints to various neuronal cellular models should be done in a careful way to build reliable and feasible testing strategies. This review addresses the use of in vitromodels for neurotoxicity research, aiming to contribute to a better understanding and guidance of in vitroneurotoxicological studies. As such, subcellular systems, namely isolated mitochondria and synaptosomes, and cellular models, including immortalized cell lines, primary cultures, co-cultures, organotypic cultures, neural stem cells and blood–brain barrier models, as well as their inherent advantages and limitations, are discussed.
- Published
- 2015
- Full Text
- View/download PDF
38. Mitoxantrone is More Toxic than Doxorubicin in SH-SY5Y Human Cells: A ‘Chemobrain’ In Vitro Study.
- Author
-
Almeida, Daniela, Pinho, Rita, Correia, Verónica, Soares, Jorge, Bastos, Maria de Lourdes, Carvalho, Félix, Costa, Vera Marisa, and Capela, João Paulo
- Subjects
MITOXANTRONE ,DOXORUBICIN ,NEUROTOXICOLOGY ,CANCER treatment complications ,MULTIPLE sclerosis treatment ,MITOCHONDRIAL membrane abnormalities - Abstract
The potential neurotoxic effects of anticancer drugs, like doxorubicin (DOX) and mitoxantrone (MTX; also used in multiple sclerosis), are presently important reasons for concern, following epidemiological data indicating that cancer survivors submitted to chemotherapy may suffer cognitive deficits. We evaluated the in vitro neurotoxicity of two commonly used chemotherapeutic drugs, DOX and MTX, and study their underlying mechanisms in the SH-SY5Y human neuronal cell model. Undifferentiated human SH-SY5Y cells were exposed to DOX or MTX (0.13, 0.2 and 0.5 μM) for 48 h and two cytotoxicity assays were performed, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) reduction and the neutral red (NR) incorporation assays. Phase contrast microphotographs, Hoechst, and acridine orange/ethidium bromide stains were performed. Mitochondrial membrane potential was also assessed. Moreover, putative protective drugs, namely the antioxidants
N -acetyl-l-cysteine (NAC; 1 mM) and 100 μM tiron, the inhibitor of caspase-3/7, Ac-DEVD-CHO (100 μM), and a protein synthesis inhibitor, cycloheximide (CHX; 10 nM), were tested to prevent DOX- or MTX-induced toxicity. The MTT reduction assay was also done in differentiated SH-SY5Y cells following exposure to 0.2 μM DOX or MTX. MTX was more toxic than DOX in both cytotoxicity assays and according to the morphological analyses. MTX also evoked a higher number of apoptotic nuclei than DOX. Both drugs, at the 0.13 μM concentration, caused mitochondrial membrane potential depolarization after a 48-h exposure. Regarding the putative neuroprotectors, 1 mM NAC was not able to prevent the cytotoxicity caused by either drug. Notwithstanding, 100 μM tiron was capable of partially reverting MTX-induced cytotoxicity in the NR uptake assay. One hundred μM Ac-DEVD-CHO and 10 nM cycloheximide (CHX) also partially prevented the toxicity induced by DOX in the NR uptake assay. MTX was more toxic than DOX in differentiated SH-SY5Y cells, while MTX had similar toxicity in differentiated and undifferentiated SH-SY5Y cells. In fact, MTX was the most neurotoxic drug tested and the mechanisms involved seem dissimilar among drugs. Thus, its toxicity mechanisms need to be further investigated as to determine the putative neurotoxicity for multiple sclerosis and cancer patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
39. Investigação de novos fármacos ansiolíticos que atuam na proteína translocadora 18 KDa (TSPO)
- Author
-
Pereira, Natália Cristina Ferraz da Silva and Capela, João Paulo Soares
- Subjects
Etifoxina ,Ciências Médicas::Medicina Básica [Domínio/Área Científica] ,Proteína Translocadora (18 KDa) (TSPO) ,Ansiedade ,Anxiety ,YL‑IPA08 ,XBD173 ,Translocator Protein (18 KDa) (TSPO) - Abstract
Submitted by azevedo@ufp.pt (azevedo@ufp.pt) on 2021-11-24T16:47:52Z No. of bitstreams: 1 PPG_19446.pdf: 844836 bytes, checksum: fa76393b2ae0615c59ae1b9671c69591 (MD5) Approved for entry into archive by azevedo@ufp.pt (azevedo@ufp.pt) on 2021-11-24T16:48:56Z (GMT) No. of bitstreams: 1 PPG_19446.pdf: 844836 bytes, checksum: fa76393b2ae0615c59ae1b9671c69591 (MD5) Made available in DSpace on 2021-11-24T16:48:56Z (GMT). No. of bitstreams: 1 PPG_19446.pdf: 844836 bytes, checksum: fa76393b2ae0615c59ae1b9671c69591 (MD5) Previous issue date: 2021-06-30
- Published
- 2021
40. Fármacos usados no tratamento da dependência de opioides
- Author
-
Silvestre, Ana Rodrigues Oliveira and Capela, João Paulo Soares
- Subjects
Neurobiology of addiction ,Opioide ,Anti-heroin vaccine ,Epidemiology ,Dependência opioide ,Opioid ,Ibudilast ,Opioid dependence ,Metadona ,Agonistas alfa-2-adrenérgicos ,Epidemiologia ,Side effects ,Efeitos secundários ,Naloxona ,Neurobiologia da adição ,Maintenance treatment ,Alpha-2-adrenergic agonists ,Ciências Médicas::Medicina Básica [Domínio/Área Científica] ,Buprenorfina ,Naloxone ,Naltrexona ,Tratamento de substituição ,Pharmacotherapy ,Naltrexone ,Buprenorphine ,Vacina anti-heroína ,Farmacoterapia ,Methadone - Abstract
Submitted by azevedo@ufp.pt (azevedo@ufp.pt) on 2021-02-01T17:09:15Z No. of bitstreams: 1 PPG_30979.pdf: 590730 bytes, checksum: e15134b91a73ef7e4f31c5420686e5ae (MD5) Approved for entry into archive by azevedo@ufp.pt (azevedo@ufp.pt) on 2021-02-01T17:09:43Z (GMT) No. of bitstreams: 1 PPG_30979.pdf: 590730 bytes, checksum: e15134b91a73ef7e4f31c5420686e5ae (MD5) Made available in DSpace on 2021-02-01T17:09:43Z (GMT). No. of bitstreams: 1 PPG_30979.pdf: 590730 bytes, checksum: e15134b91a73ef7e4f31c5420686e5ae (MD5) Previous issue date: 2020-11-24
- Published
- 2020
41. Novos fármacos hipnóticos antagonistas da orexina
- Author
-
Vieira, Fábio Miguel Fernandes and Capela, João Paulo Soares
- Subjects
Benzodiazepines ,Ciências Médicas::Medicina Básica [Domínio/Área Científica] ,Insomnia ,Orexina ,Indústria farmacêutica ,Benzodiazepinas ,Suvorexant ,Orexin ,Insónia ,pharmaceutical industry - Abstract
A insónia constitui atualmente um grande problema de saúde pública, cuja intervenção a nível individual ou num âmbito mais vasto são necessárias. O mercado de fármacos, usados no tratamento deste tipo de distúrbios, é presentemente dominado pelas benzodiazepinas e pelos hipnóticos não benzodiazepínicos, tendo o tratamento por base uma intervenção farmacológica e não farmacológica. Como nova classe de fármacos desenvolvida com o intuito de induzir o sono sem os efeitos colaterais produzidos pelas benzodiazepinas, surgiram os antagonistas da orexina, que em vários estudos demonstraram resultados bastante promissores. Neste seguimento surge o Suvorexant, o primeiro antagonista seletivo dos recetores orexina 1 e 2 a ser aprovado para o tratamento da insónia. Este fármaco proporciona uma alternativa única para pacientes com insónia que não toleram benzodiazepinas ou hipnóticos não benzodiazepínicos ou em casos de ineficácia da terapêutica. O suvorexant é geralmente seguro e bem tolerado nos pacientes, no entanto os ensaios clínicos desta classe ainda apresentam imensas limitações. Em conformidade com o que aconteceu com muitos outros fármacos inovadores, ao longo dos anos milhares de pacientes serão expostos a fármacos cujo conhecimento científico e a segurança são muito limitados. O médico e o farmacêutico têm assim um papel decisivo na identificação, aconselhamento e tratamento dos distúrbios do sono. Um fármaco nunca deve ser a primeira hipótese terapêutica, devendo ser sempre considerados todos os seus riscos e benefícios associados. A indústria farmacêutica está cada vez mais a demonstrar interesse por este tipo de fármacos, havendo várias moléculas promissoras atualmente em estudo, com o objetivo de se obter a molécula ideal, com o mínimo de efeitos adversos. Insomnia is currently a major public health problem, who requires intervention at the individual or broader level. The market for drugs, used to treat this type of disorders is currently dominated by benzodiazepines and non-benzodiazepine sedatives which treatment is based on a pharmacological and non-pharmacological intervention. As a new class of drugs developed to induce sleep without the side effects produced by benzodiazepines, orexin antagonists appeared, which in several studies have shown very promising results. In this way suvorexant appears as the first selective antagonist of orexin 1 and 2 receptors to be approved for the treatment of insomnia. This drug provides a unique alternative for insomnia patients who do not tolerate benzodiazepines or non-benzodiazepine hypnotics or in cases of ineffective therapy. Suvorexant is generally safe and well tolerated in patients, however the clinical trials of this class still have some limitations. In line with what has happened to many other innovative drugs, over the years thousands of patients will be exposed to drugs whose scientific knowledge and safety are very limited. The physician and pharmacist thus play a decisive role in the identification, counseling and treatment of sleep disorders. A drug should never be the in the first place as the first therapeutic hypothesis, and the associate risks and benefits should always be considered. The pharmaceutical industry is increasingly focused on development of this type of drugs, with several promising molecules currently under study, in order to obtain the ideal molecule with the least adverse effects.
- Published
- 2017
42. Evolução da notificação espontânea pelos farmacêuticos ao Sistema Nacional de Farmacovigilância
- Author
-
Faria, Jéssica Madalena Gonzaga and Capela, João Paulo Soares
- Subjects
Pharmacovigilance ,Ciências Médicas::Medicina Básica [Domínio/Área Científica] ,Notification of adverse effects ,Spontaneous notifications ,Notifications by pharmacists ,Adverse reactions - Abstract
A notificação espontânea de reações adversas é importante, uma vez que é a única forma de monitorizar continuamente o medicamento depois da sua comercialização. Esta notificação depende dos utentes mas principalmente dos profissionais de saúde, nomeadamente dos farmacêuticos, permitindo uma rápida atuação por parte das autoridades competentes. Esta tese tem como objetivo avaliar as notificações ao sistema nacional de farmacovigilância por parte dos farmacêuticos num período compreendido entre o ano 2000 e o ano 2016 efetuando a correlação com o número de farmacêuticos inscritos na Ordem dos Farmacêuticos no mesmo período. A metodologia aplicada de acordo com os objetivos traçados foi a pesquisa em base de dados científicas através de palavras-chaves e contactando diretamente as entidades responsáveis, nomeadamente o Infarmed e a Ordem dos Farmacêuticos para obtenção do número de notificações espontâneas e a evolução do número de farmacêuticos inscritos, respetivamente. O número de notificações espontâneas tem vindo a aumentar gradualmente, sendo os principais notificadores atualmente a indústria farmacêutica, seguindo-se os médicos e os farmacêuticos. O número de notificações espontâneas por parte dos farmacêuticos tem acompanhado o crescimento das inscrições junto da Ordem dos Farmacêuticos, no entanto representa apenas 13,5% da notificação espontâneas em Portugal. Os farmacêuticos hospitalares são os que mais notificam apesar de representarem 8% da classe farmacêutica. Em suma, é necessário educar e incentivar os farmacêuticos para notificarem reações adversas a medicamentos ao Sistema Nacional de Farmacovigilância. Spontaneous reporting of adverse reactions is important as it is the only way to continuously monitor the drug after it is marketed. This notification depends on the users but mainly on the health professionals, in particular the pharmacists, allowing a fast action on the part of the competent authorities. This thesis aims to evaluate the notifications to the national system of pharmacovigilance by pharmacists in a period between 2000 and 2016 correlating with the number of pharmacists registered in the Order of Pharmacists in the same period. The methodology applied in accordance with the objectives outlined was the research in scientific databases through keywords and directly contacting the responsible entities, namely the Infarmed and the Pharmacists Order to obtain the number of spontaneous notifications and the evolution of the number of registered pharmacists, respectively. The number of spontaneous notifications has gradually increased, with the main notifiers currently being the pharmaceutical industry, followed by doctors and pharmacists. The number of spontaneous notifications by pharmacists has accompanied the growth of registrations with the Pharmacists' Order, however it represents only 13,5% of the notification in Portugal. Hospital pharmacists report the most despite representing 8% of the pharmaceutical class. In short, it is necessary to educate and encourage pharmacists to report adverse drug reactions to the National Pharmacovigilance System.
- Published
- 2017
43. Pesquisa de novos fármacos hipnóticos alternativos às benzodiazepinas
- Author
-
Cruz, Ana Filipa Moreira Da and Capela, João Paulo Soares
- Subjects
Ciências Médicas::Medicina Básica [Domínio/Área Científica] ,Insomnia ,Benzodiazepine ,New hypnotic drugs ,Epilvanserin ,Melatonine receptors ,New orexine receptors antagonist - Abstract
A insónia é uma doença multifacetada que pode estar associada a vários fatores e patologias. Devido à sua elevada prevalência causa um forte impacto económico e social tornando-se dispendiosa quer para o doente quer para o sistema de saúde. Esta patologia afeta o desempenho diário do paciente dado que a qualidade do sono é comprometida. O tratamento farmacológico da insónia fundamenta-se, essencialmente, em fármacos cujo mecanismo de ação envolve os recetores GABAA. As benzodiazepinas, o principal grupo farmacológico utilizado para este fim, causa muitos efeitos adversos e obriga além disso, à interrupção gradual e controlada do tratamento devido à síndrome de abstinência. A realização desta dissertação tem como principal objetivo descrever e analisar a atual pesquisa de novos fármacos hipnóticos alternativos às benzodiazepinas. Para a realização deste trabalho de pesquisa bibliográfica, efetuou-se uma procura de artigos em vários motores de busca como “Pubmed”, “Science Direct”, “b-on”, “upToDate” bem como o “Google Académico”. A partir dos motores de busca, utilizaram-se as palavras-chave em inglês “insomnia”, “benzodiazepine”, “new hypnotic drugs”, “new orexine receptors antagonist”, “epilvanserin” e “melatonine receptors”. Neste trabalho, foram também incluídas informações contidas em livros científicos bem como em publicações de entidades oficiais sobre o tema em discussão. Os novos fármacos com potencial terapêutico para o tratamento desta patologia englobam os agonistas da melatonina, antagonistas 5HT2A e os antagonistas orexinérgicos. Atualmente apenas os agonistas da melatonina e os antagonistas da orexina é que podem ser usados na prática clínica. Todas estas alternativas apresentam diversas vantagens relativamente à terapêutica farmacológica standard usada para tratar a insónia. Contudo devido ao recente desenvolvimento destes fármacos, serão necessários mais estudos e ensaios clínicos para uma melhor compreensão da sua eficácia clínica no tratamento da insónia e de outras patologias. Insomnia is a multifaceted disease that may be associated with various factors and conditions. Due to its high prevalence causes a severe economic and social impact becoming expensive for the patient and for the healthcare system. This disease affects the daily performance of the patient because the quality of sleep is compromised. Insomnia´s treatment has been based on drugs whose mechanism of action involves the GABAA receptor. Benzodiazepines, the main pharmacological group used for this purpose, causes many adverse effects and requires furthermore, the controlled and gradual discontinuation of therapy due to withdrawal syndrome. The realization of this dissertation aims to describe and analyze the current research of new alternative hypnotic drugs to benzodiazepines.To this end a bibliographic research was performed on the main search engines: “Pubmed”, “Science Direct”, “b-on”, “UpToDate” and “Google Scholar”, are used key-words “insomnia”, “benzodiazepine”, “new hypnotic drugs”, “new orexine antagonist receptors”, “epilvanserin” and “melatonine receptors”. In this work were also included information of scientific books as well as in official entities publications on the subject under discussion. The new drugs with therapeutic potential for the treatment of this disorder include melatonin agonists, 5HT2A antagonists and orexinergic antagonists. Currently only melatonin agonists and orexin antagonists can be used in clinical practice. All these alternatives have several advantages over standard therapy used to treat insomnia. Though, due to the recent development of these drugs further studies and clinical trials will be required for a better understanding of their effectiveness in treating insomnia and other diseases as well.
- Published
- 2016
44. riscos para a saúde
- Author
-
Lopes, Márcia Daniela Moreira and Capela, João Paulo Soares
- Subjects
Dietary supplement ,Weight loss ,Cafeína ,Perda de peso ,Termogénese ,Caffeine ,Nutrição ,Thermogenesis ,Suplemento alimentar ,Nutrition - Abstract
Trabalho Complementar apresentado à Universidade Fernando Pessoa como parte dos requisitos para obtenção do grau de licenciada em Ciências da Nutrição Linha geral: Aumentar o metabolismo é o objetivo primário da maioria dos suplementos alimentares termogénicos presentes no mercado, a presença da cafeína nestes suplementos tem mostrado promover a lipólise, a oxidação de gordura e com eventual perda de peso. Objetivo: Estudar os suplementos alimentares termogénicos contendo cafeína existentes no mercado português fazendo uma comparação entre os mesmos, bem como dar a conhecer os riscos associados à toma das doses de cafeína que estes contêm. Metodologia: Para a pesquisa científica deste trabalho, usou-se a PubMed, b-on, Science direct e google académico como bases de dados. Para a pesquisa dos suplementos alimentares referidos como termogénicos à venda em Portugal, foi efetuada uma pesquisa em pontos de venda desses produtos incluindo sítios da internet. Resultados: Da análise do conteúdo dos suplementos existentes no mercado português resultou a compilação de 43 suplementos alimentares termogénicos contendo cafeína. A dose mediana de cafeína diária recomendada pelo fabricante é de 250mg, o limite inferior do intervalo de confiança a 95% da mediana correspondeu a 200mg e o limite superior a 400mg. Verificou-se ainda que o valor mínimo de dose diária recomendada corresponde a 64mg, pertencendo ao suplemento “Reduxdren” do produtor “FGM04”, e o valor máximo a 1920mg, no suplemento “Xcess ultra concentrate” da “Xcore”. Relativamente às quantidades presentes por cápsula/dose única, pôde-se verificar que o teor mediano de cafeína é de 100mg, o limite inferior do intervalo de confiança a 95% da mediana é de 66.7mg, e o limite superior a 112.5mg, já o valor mínimo correspondeu a 30mg no suplemento “Cutgenic for men” cujo responsável pela comercialização é a “Bodyraise” e o valor máximo a 480mg no suplemento “Xcess ultra concentrate” da “Xcore”. Conclusão: A cafeína está presente na maioria dos suplementos alimentares termogénicos, pela sua capacidade em promover a excitabilidade do sistema nervoso, (17, 26) e pela sua capacidade em promover a termogénese que ocorre principalmente pela sua aptidão em se ligar aos recetores de adenosina no cérebro, primariamente A1 e A2a, sendo um antagonista (10, 13, 18, 19, 21, 24, 27, 28, 29, 30). Para consumidores habituais de cafeína pensa-se que a dose diária não deve exceder os 400mg, porém neste estudo verificou-se que 11 suplementos excedem este valor, e para consumidores não habituais de cafeína a dose máxima recomendada é de 200mg/dia e constatou-se que 26 dos 43 suplementos excediam esta quantidade (18, 35). A presença de cafeína nos suplementos parece contribuir para a perda de peso, no entanto existem poucos estudos que comprovem a sua segurança, revelando assim que mais pesquisas nesta área são necessárias. Background: Increased metabolism is the primary goal of most thermogenic supplements on the market, the presence of caffeine in these supplements has been shown to promote lipolysis, fat oxidation and possible weight loss. Objective: To study the thermogenic supplements containing caffeine existing in the Portuguese market by making a comparison between them and bringing to light the facts and risks associated with taking the doses of caffeine they contain. Methodology: It was used for scientific research PubMed, b-on, Science direct and Academic Google as databases. For the research of dietary supplements that are for sale in Portugal and were mentioned as thermogenic, it was carried out a investigation at selling points of these products, including the internet. Results: The analysis of the existing supplements in the Portuguese market resulted in the compilation of 43 thermogenic supplements containing caffeine. The median daily dosage of caffeine recommended by the manufacture is 250mg, the lowest limit of the confidence interval to 95 % of the median corresponded to 200mg and the highest limit corresponded to 400mg. It was also found that the minimum daily dose recommended corresponds to 64mg, belonging to supplement “Reduxdren” producer “FGM04” and 1920mg at maximum value, belonging to supplement “Xcess ultra concentrate” of “Xcore”. In regard to the quantities present per capsule/single dose, the caffeine content is 100mg median, the lower confidence interval of 95% of the median limit is 66.7mg and the upper limit is 112.5mg, in comparison to the minimum value corresponding to 30mg in the supplement “Cutgenic for men” whose “Bodyraise” is responsible for marketing and the maximum amount in the supplement “Xcess ultra concentrate” from “Xcore”. Conclusion: Caffeine is present in most thermogenic supplements for their ability to promote the excitability of the nervous system (17, 26), and its capacity to promote thermogenesis which occurs primarily by its ability to bind to adenosine receptors in the brain, primarily A1 e A2a, acting as an antagonist (10, 13, 18, 19, 21, 24, 27, 28, 29, 30). For regular consumers of caffeine it is believed that the daily dose should not exceed 400mg, but in this study it was found that 11 supplements exceed this value, and for noncaffeine usual consumers the maximum dose recommended is 200mg/day, and it was found that 26 of the 43 supplements exceed this quantity (18, 35). The presence of caffeine in supplements seems to contribute to weight loss, however there are few studies that prove its safety, thus revealing that further research is needed. N/A
- Published
- 2016
45. Novos fármacos anticoagulantes orais alternativos à varfarina
- Author
-
Martins, Ana Ferreira and Capela, João Paulo Soares
- Abstract
Projeto de Pós-Graduação/Dissertação apresentado à Universidade Fernando Pessoa como parte dos requisitos para obtenção do grau de Mestre em Ciências Farmacêuticas Atualmente as doenças cardiovasculares são uma das principais causas de mortalidade e morbilidade nos países desenvolvidos. A terapêutica anticoagulante oral consiste num tratamento realizado com o principal objetivo de reduzir a ocorrência de fenómenos trombóticos mas sem aumentar significativamente o risco hemorrágico. A varfarina é dos anticoagulantes orais mais utilizados na prática clínica a nível mundial, mas, face às limitações deste fármaco resultantes do lento início de ação farmacológica, da janela terapêutica estreita, das múltiplas interações medicamentosas e alimentares e do potencial risco de complicações hemorrágicas, a indústria tem procurado novas alternativas farmacológicas capazes de superar estes problemas. Com este trabalho pretende-se fazer uma revisão bibliográfica sobre os novos grupos de fármacos anticoagulantes orais que constituem alternativa à varfarina, fazendo previamente uma revisão sobre toda a fisiologia da coagulação sanguínea e patologias associadas. Atualmente, a investigação farmacológica centra-se no desenvolvimento de novas moléculas, inibidoras de agentes específicos do sistema da coagulação, com um padrão farmacodinâmico e farmacocinético previsível e consistente, destacando-se os inibidores diretos da trombina, que incluem o dabigatrano, e os inibidores do fator Xa, que se focam essencialmente no rivaroxabano e no apixabano. Apenas com mais ensaios clínicos será possível saber da segurança destes novos fármacos e da possibilidade destes novos alvos farmacológicos serem alternativas inequívocas à varfarina. Só então poderemos saber se estes fármacos conseguem destronar a varfarina como o principal anticoagulante oral. Nowadays, the cardiovascular diseases are the major cause for mortality and morbidity at the developing countries. The oral anticoagulant therapy is a treatment conducted with the primary goal of reducing the occurrence of thrombotic phenomena but without increasing the risk of bleeding significantly. Warfarin is the most world widely used oral anticoagulant in clinical practice, but given the drug limitations from the slow onset of pharmacological action, narrow therapeutic window, the multiple medicines and food interactions and the potential risk of bleeding complications, industry has sought new pharmacological alternatives capable of overcoming these problems. With this work, we intend to make a review on the new groups of oral anticoagulants that are alternative to warfarin, making previously, a review of the blood clotting physiology and associated pathologies. Currently, the pharmacological research focuses on the development of new molecules, specific inhibitors agents of the coagulation system, with pharmacodynamics pattern and pharmacokinetic predictable and consistent, highlighting the direct thrombin inhibitors, including dabigatran, and inhibitors of factor Xa, which focus primarily on rivaroxaban and apixaban. Only with more clinical trials will be possible to know the safety of these new medicines and the possibility of these new pharmacological targets are clear alternatives to warfarin. Only then can we know whether these drugs can dethrone warfarin as the main oral anticoagulant.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.